Chargement en cours...
Magnitude of benefit of the addition of bevacizumab to first-line chemotherapy for metastatic colorectal cancer: meta-analysis of randomized clinical trials
BACKGROUND: Although the addition of bevacizumab to 1(st )line chemotherapy provides a significant survival benefit for advanced colorectal cancer, the magnitudes of both advantages and toxicities have not been extensively investigated. METHODS: A literature-based meta-analysis was conducted; Hazard...
Enregistré dans:
| Auteurs principaux: | , , , , , , , , , , , , |
|---|---|
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
BioMed Central
2010
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2890550/ https://ncbi.nlm.nih.gov/pubmed/20504361 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1756-9966-29-58 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|